Prescription medicine
Vilazodone Brand names: Viibryd
Vilazodone (Viibryd) is a prescription medicine with an FDA approval on record since 2011. FDA's NDC Directory lists it from 12 generic labelers, and pharmacies paid $0.732 per vilazodone HCl 10 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
- Boxed warning
Check it at the source: the vilazodone FDA label on DailyMed (effective May 22, 2024, Teva Pharmaceuticals, Inc.); the NDA 22567 record on Drugs@FDA; every vilazodone label on DailyMed.
Highlights of the record
FDA label of May 22, 2024; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
SUICIDAL THOUGHTS AND BEHAVIORS.
Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )]. Vilazodone hydrochloride tablets are not approved for use in pediatric patients [see Use in Specific Populations ( 8.4) ]. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Antidepressants increase the risk of suicidal thoughts and behaviors in pediatric and young adult patients. ( 5.1 ) Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors. ( 5.1 ) Vilazodone hydrochloride tablets are not approved for use in pediatric patients.
Used for
From the label: indications and usageVilazodone hydrochloride tablets are indicated for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies ( 14 )].
Forms and strengths
- 10 mg
- 20 mg
- 40 mg
Tablet; film-coated tablet.
On the market
- Earliest approval on file
- January 21, 2011 Viibryd, Abbvie; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 5 first September 30, 2019; 5 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 13 of which 12 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $0.732 per tablet Vilazodone HCl 10 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 9,170 through July 30, 2026
What is vilazodone used for?
From the label: indications and usageVilazodone hydrochloride tablets are indicated for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies ( 14 )]. Vilazodone hydrochloride tablets are indicated for the treatment of major depressive disorder (MDD) in adults.
Conditions named in the indications of vilazodone's FDA labels, with every medicine labeled for each:
Source: FDA drug label (Vilazodone Hydrochloride), Teva Pharmaceuticals, Inc., effective May 22, 2024 (SPL set 3a4745a0-de23-4b40-923e-0d7dfe6b8634), via openFDA; the full label on DailyMed
What does the patient leaflet for vilazodone say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about vilazodone hydrochloride tablets?Vilazodone hydrochloride tablets may cause serious side effects, including: Increased risk of suicidal thoughts or actions in some children, adolescents, and young adults. Vilazodone hydrochloride tablets and other antidepressant medicines may increase suicidal thoughts or actions in some people 24 years of age and younger, especially within the first few months of treatment or when the dose is changed. Vilazodone hydrochloride tablets are not for use in children. Depression or other serious mental illnesses are the most important causes of suicidal thoughts or actions. Some people may have a higher risk of having suicidal thoughts or actions. These include people who have (or have a family history of) depression, bipolar illness (also called manic-depressive illness) or have a history of suicidal thoughts or actions. How can I watch for and try to prevent suicidal thoughts and actions? Pay close attention to any changes, especially sudden changes in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions. This is very important when an antidepressant medicine is started or when the dose is changed. Call your healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings. Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms. […]
From the patient leaflet: What should I avoid while taking vilazodone hydrochloride tablet?Do not drive, operate heavy machinery, or do other dangerous activities until you know how vilazodone hydrochloride tablets affect you. Vilazodone hydrochloride tablets can cause sleepiness or may affect your ability to make decisions, think clearly, or react quickly. Avoid drinking alcohol during treatment with vilazodone hydrochloride tablets.
From the patient leaflet: How should I store vilazodone hydrochloride tablets?Store vilazodone hydrochloride tablets at room temperature between 68°F to 77°F (20°C to 25°C). Keep vilazodone hydrochloride tablets and all medicines out of the reach of children.
Source: FDA drug label (Vilazodone Hydrochloride), Teva Pharmaceuticals, Inc., effective May 22, 2024 (SPL set 3a4745a0-de23-4b40-923e-0d7dfe6b8634), via openFDA; the full label on DailyMed
Is there a generic for vilazodone (Viibryd)?
The FDA approved the first generic vilazodone on September 30, 2019. 5 generic applications are approved; 5 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists vilazodone from 12 labelers under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 2011 earliest approval on file
- 2019 first generic approved
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for vilazodone (Viibryd)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.732 per Vilazodone HCl 10 mg tablet, down 29% from $1.03 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Vilazodone HCl 20 mg tablet (generic)
- Viibryd 10 mg tablet (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Vilazodone HCl 10 mg tablet | Generic | $0.732 per tablet | $21.95 | -29% |
| Vilazodone HCl 20 mg tablet | Generic | $0.706 per tablet | $21.17 | -24% |
| Vilazodone HCl 40 mg tablet | Generic | $0.840 per tablet | $25.20 | -22% |
| Viibryd 10 mg tablet | Brand | $12.17 per tablet | $365.23 | +5% |
| Viibryd 20 mg tablet | Brand | $12.18 per tablet | $365.42 | +5% |
| Viibryd 40 mg tablet | Brand | $12.19 per tablet | $365.77 | +5% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the vilazodone label say about other medicines?
The vilazodone label names 17 other medicines in its interaction, contraindication or warning sections. The labels of 2 other medicines name vilazodone. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Aspirin | warnings and precautions | Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk. ( 5.3 ) Activation of Mania/Hypomania: |
| Buspirone | drug interactions | Concomitant Drug Name or Drug Class: Other Serotonergic Drugs; Clinical Rationale: Concomitant use of vilazodone hydrochloride with other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. … |
| Carbamazepine | drug interactions | Concomitant Drug Name or Drug Class: Strong CYP3A4 Inducers (e.g., carbamazepine, phenytoin, rifampin); Clinical Rationale: The concomitant use of vilazodone hydrochloride and strong CYP3A4 inducers decreased the exposure of vilazodone compared to the use of vilazodone hydrochloride alone [see Clinical Pharmacology … |
| Clarithromycin | drug interactions | Concomitant Drug Name or Drug Class: Strong CYP3A4 Inhibitors (e.g., itraconazole, clarithromycin, voriconazole); Clinical Rationale: The concomitant use of vilazodone hydrochloride and strong CYP3A4 inhibitors increased the exposure of vilazodone compared to the use of vilazodone hydrochloride alone [see Clinical … |
| Digoxin | drug interactions | Concomitant use of vilazodone hydrochloride increased digoxin concentrations [see Clinical Pharmacology ( 12.3 )]. |
| Fentanyl | warnings and precautions | The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. … |
| Itraconazole | drug interactions | Concomitant Drug Name or Drug Class: Strong CYP3A4 Inhibitors (e.g., itraconazole, clarithromycin, voriconazole); Clinical Rationale: The concomitant use of vilazodone hydrochloride and strong CYP3A4 inhibitors increased the exposure of vilazodone compared to the use of vilazodone hydrochloride alone [see Clinical … |
| Linezolid | contraindications | CONTRAINDICATIONS Vilazodone hydrochloride tablets are contraindicated in: Patients taking, or within 14 days of stopping, monoamine oxidase inhibitors (MAOIs), including MAOIs such as linezolid or intravenous methylene blue, because of an increased risk of serotonin syndrome [see Warnings and Precautions ( 5.2 ) … |
| Lithium | drug interactions | Concomitant Drug Name or Drug Class: Other Serotonergic Drugs; Clinical Rationale: Concomitant use of vilazodone hydrochloride with other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. … |
| Meperidine | warnings and precautions | The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. … |
| Methadone | warnings and precautions | The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. … |
| Methylene blue | contraindications | CONTRAINDICATIONS Vilazodone hydrochloride tablets are contraindicated in: Patients taking, or within 14 days of stopping, monoamine oxidase inhibitors (MAOIs), including MAOIs such as linezolid or intravenous methylene blue, because of an increased risk of serotonin syndrome [see Warnings and Precautions ( 5.2 ) … |
| Phenytoin | drug interactions | Concomitant Drug Name or Drug Class: Strong CYP3A4 Inducers (e.g., carbamazepine, phenytoin, rifampin); Clinical Rationale: The concomitant use of vilazodone hydrochloride and strong CYP3A4 inducers decreased the exposure of vilazodone compared to the use of vilazodone hydrochloride alone [see Clinical Pharmacology … |
| Rifampin | drug interactions | Concomitant Drug Name or Drug Class: Strong CYP3A4 Inducers (e.g., carbamazepine, phenytoin, rifampin); Clinical Rationale: The concomitant use of vilazodone hydrochloride and strong CYP3A4 inducers decreased the exposure of vilazodone compared to the use of vilazodone hydrochloride alone [see Clinical Pharmacology … |
Every other medicine the vilazodone label names
| Medicine named | Section | What the label says |
|---|---|---|
| Tramadol | warnings and precautions | … tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. … |
| Voriconazole | drug interactions | Concomitant Drug Name or Drug Class: Strong CYP3A4 Inhibitors (e.g., itraconazole, clarithromycin, voriconazole); Clinical Rationale: The concomitant use of vilazodone hydrochloride and strong CYP3A4 … |
| Warfarin | drug interactions | For patients taking warfarin, carefully monitor the international normalized ratio (INR) when initiating, titrating, or discontinuing vilazodone hydrochloride [see Warnings and Precautions ( 5.3 )]. |
Other labels that name vilazodone
Source: FDA drug label (Vilazodone Hydrochloride), Teva Pharmaceuticals, Inc., effective May 22, 2024 (SPL set 3a4745a0-de23-4b40-923e-0d7dfe6b8634), via openFDA; the full label on DailyMed
What do FAERS reports show for vilazodone?
The FDA Adverse Event Reporting System holds 9,170 reports that list vilazodone among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 185 are coded as a death and 1,012 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as vilazodone?
30 other medicines are given the same way (oral) and in the same FDA class as vilazodone or labeled mainly for the same use (depression), the same class first. Depression lists all 37 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Bupropion | Depression | 73 labelers | $0.0785 per tablet 150 mg tablet | No current entry |
| Venlafaxine | Depression | 62 labelers | $0.0799 per capsule 75 mg capsule | No current entry |
| Aripiprazole | Depression | 47 labelers | $0.110 per tablet 5 mg tablet | No current entry |
| Fluoxetine | Depression | 59 labelers | $0.0519 per capsule 40 mg capsule | No current entry |
| Sertraline | Depression | 48 labelers | $0.0507 per tablet 100 mg tablet | No current entry |
| Amitriptyline | Depression | 36 labelers | $0.03 per tablet 10 mg tablet | No current entry |
| Duloxetine | Depression | 45 labelers | $0.102 per capsule 30 mg capsule | No current entry |
| Doxepin | Depression | 48 labelers | $0.0779 per capsule 10 mg capsule | No current entry |
Every medicine labeled for the same conditions as vilazodone
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does vilazodone compare with medicines for the same use?
4 side-by-side pages set vilazodone beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to vilazodone
- 30 medicines for the same use
- Vilazodone side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other